David Carroll - Mar 18, 2022 Form 4 Insider Report for IVERIC bio, Inc. (ISEE)

Role
CFO
Signature
/s/ Todd Anderman, as Attorney-in-Fact for David Carroll
Stock symbol
ISEE
Transactions as of
Mar 18, 2022
Transactions value $
-$184,619
Form type
4
Date filed
3/22/2022, 04:44 PM
Previous filing
Jan 4, 2022
Next filing
Mar 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ISEE Common Stock Options Exercise $11.9K +8.24K +12.43% $1.45* 74.5K Mar 18, 2022 Direct F1, F2
transaction ISEE Common Stock Sale -$197K -11.6K -15.52% $17.00 62.9K Mar 18, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISEE Stock Option (right to buy) Options Exercise $0 -8.24K -8.24% $0.00 91.8K Mar 18, 2022 Common Stock 8.24K $1.45 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2021.
F2 This total includes 764 shares acquired by the Reporting Person on March 15, 2022, under the Registrant's 2016 Employee Stock Purchase Plan that were not previously reported.
F3 The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.02 per share on March 18, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
F4 This stock option award was granted on December 12, 2018 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.